GILD

134.06

1.64% -2.24

시간 외 거래: 132.00 -2.06 -1.54%

길리어드 사이언스 (GILD)

개요 뉴스 가격 이력 옵션 체인 Financials GILD 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$136.30

열려 있는:

$136.495

하루 거래량:

7.98M

Relative Volume:

1.25

시가총액:

$166.40B

수익:

$29.45B

순이익/손실:

$8.51B

주가수익비율:

19.77

EPS:

6.7823

순현금흐름:

$9.46B

1주 성능:

+2.46%

1개월 성능:

-3.41%

6개월 성능:

+12.81%

1년 성능:

+35.55%

1일 변동 폭

$133.76

$136.50

1주일 범위

$129.01

$136.75

52주 변동 폭

$95.30

$157.29

길리어드 사이언스 Stock (GILD) Company Profile

명칭

Gilead Sciences Inc

부문

Healthcare (1107)

산업

Drug Manufacturers - General (20)

전화

(650) 574-3000

주소

333 LAKESIDE DR, FOSTER CITY, CA

직원

17,000

트위터

@GileadSciences

다음 수익 날짜

2026-05-07

최신 SEC 제출 서류

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, AZN, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
GILD Gilead Sciences Inc	134.06	169.18B	29.45B	8.51B	9.46B	6.7823
LLY Lilly Eli Co	974.96	880.19B	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	222.51	540.71B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	202.71	362.65B	62.82B	3.62B	17.82B	2.0331
AZN Astrazeneca Plc	182.52	286.78B	60.48B	10.40B	8.05B	3.3297
NVS Novartis Ag Adr	145.39	283.08B	54.66B	13.58B	16.05B	7.0171

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-10	개시	Jefferies	Buy
2026-02-20	개시	Barclays	Equal Weight
2026-02-11	재확인	Needham	Buy
2026-01-07	재개	UBS	Buy
2025-11-24	재개	Truist	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-08-19	업그레이드	Daiwa Securities	Neutral → Outperform
2025-08-08	업그레이드	Truist	Hold → Buy
2025-07-25	업그레이드	Needham	Hold → Buy
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-03-04	재확인	Oppenheimer	Outperform
2025-02-18	업그레이드	Deutsche Bank	Hold → Buy
2025-02-13	업그레이드	DZ Bank	Hold → Buy
2025-01-10	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-11-14	개시	Citigroup	Buy
2024-11-08	다운그레이드	Maxim Group	Buy → Hold
2024-10-21	업그레이드	Leerink Partners	Market Perform → Outperform
2024-10-17	개시	Bernstein	Outperform
2024-10-07	업그레이드	Wells Fargo	Equal Weight → Overweight
2024-07-08	업그레이드	Raymond James	Mkt Perform → Outperform
2024-05-01	재확인	Maxim Group	Buy
2024-04-24	업그레이드	HSBC Securities	Reduce → Hold
2024-02-22	다운그레이드	Truist	Buy → Hold
2023-11-09	개시	Deutsche Bank	Hold
2023-09-08	업그레이드	BofA Securities	Neutral → Buy
2023-09-06	개시	HSBC Securities	Reduce
2023-07-24	재확인	Barclays	Equal Weight
2023-05-16	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-04-28	재개	Piper Sandler	Overweight
2023-01-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	재개	BofA Securities	Neutral
2022-12-09	다운그레이드	DZ Bank	Buy → Hold
2022-10-31	업그레이드	Barclays	Underweight → Equal Weight
2022-10-28	재확인	BMO Capital Markets	Market Perform
2022-10-28	재확인	Cowen	Outperform
2022-10-28	재확인	JP Morgan	Overweight
2022-10-28	재확인	Jefferies	Buy
2022-10-28	업그레이드	Piper Sandler	Neutral → Overweight
2022-10-28	재확인	RBC Capital Mkts	Outperform
2022-10-28	업그레이드	Truist	Hold → Buy
2022-10-28	재확인	Wells Fargo	Equal Weight
2022-10-04	업그레이드	JP Morgan	Neutral → Overweight
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-02-28	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2022-02-02	재확인	BMO Capital Markets	Outperform
2022-02-02	재확인	BofA Securities	Neutral
2022-02-02	재확인	RBC Capital Mkts	Outperform
2022-02-02	재확인	Truist	Hold
2022-02-02	재확인	Wells Fargo	Equal Weight
2022-01-28	업그레이드	Argus	Hold → Buy
2022-01-06	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	재개	Wells Fargo	Equal Weight
2021-12-06	개시	Goldman	Neutral
2021-11-19	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-11-19	재개	Piper Sandler	Neutral
2021-10-20	재개	Cowen	Outperform
2021-07-30	재확인	BMO Capital Markets	Market Perform
2021-07-30	재확인	RBC Capital Mkts	Outperform
2021-04-01	업그레이드	Bernstein	Mkt Perform → Outperform
2021-03-30	업그레이드	Redburn	Neutral → Buy
2021-01-19	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	업그레이드	Guggenheim	Neutral → Buy
2020-11-03	재개	Morgan Stanley	Equal-Weight
2020-10-28	개시	UBS	Neutral
2020-09-30	재개	Jefferies	Buy
2020-09-15	업그레이드	Maxim Group	Hold → Buy
2020-07-31	재확인	Credit Suisse	Neutral
2020-07-31	재확인	Morgan Stanley	Equal-Weight
2020-07-31	재확인	Piper Sandler	Overweight
2020-07-31	재확인	RBC Capital Mkts	Outperform
2020-07-31	재확인	SunTrust	Hold
2020-07-31	재확인	Wells Fargo	Equal Weight
2020-07-20	업그레이드	Credit Suisse	Underperform → Neutral
2020-06-03	업그레이드	SVB Leerink	Mkt Perform → Outperform
2020-05-26	업그레이드	SunTrust	Sell → Hold
2020-05-01	다운그레이드	JP Morgan	Overweight → Neutral
2020-05-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-05-01	다운그레이드	SunTrust	Hold → Sell
2020-04-27	다운그레이드	UBS	Buy → Neutral
2020-04-20	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2020-04-20	다운그레이드	Wells Fargo	Overweight → Equal Weight
2020-04-17	다운그레이드	CFRA	Hold → Sell

모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

09:23 AM

Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results - MarketBeat

09:23 AM

09:05 AM

Gilead Sciences (GILD) Reports Q1 Earnings Beat, Updates EPS Gui - GuruFocus

09:05 AM

07:02 AM

Gilead Sciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:GILD) 2026-05-07 - Seeking Alpha

07:02 AM

06:33 AM

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. - Barron's

06:33 AM

06:22 AM

Will Anito-Cel Rescue Gilead’s Cell Therapy Business? - Citeline News & Insights

06:22 AM

06:18 AM

Gilead slips despite Q1 beats as it now expects 2026 loss per share - MSN

06:18 AM

06:00 AM

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore

06:00 AM

05:22 AM

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions - Reuters

05:22 AM

05:15 AM

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance UK

05:15 AM

05:12 AM

Gilead earnings show HIV drugs continue to shine. Why the guidance cut? - MSN

05:12 AM

05:07 AM

Gilead Sciences falls 4% as acquired IPR&D charges impact full-year earnings guidance - Investing.com Nigeria

05:07 AM

05:04 AM

Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance - ChartMill

04:41 AM

04:39 AM

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses - WSJ

04:39 AM

04:38 AM

Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue - StockStory

04:38 AM

04:32 AM

Earnings snapshot: Gilead beats Q1 estimates but guides for FY26 loss - MSN

04:32 AM

GILEAD SCIENCES ($GILD) Releases Q1 2026 Earnings - Quiver Quantitative

04:32 AM

04:13 AM

Gilead Sciences Q1 Adjusted Earnings, Revenue Rise; Lowers Full-Year EPS Guidance - marketscreener.com

04:13 AM

04:09 AM

(GILD) Gilead Sciences Now Expects 2026 Adjusted Loss Per Share Range $1.05-$0.65, vs. FactSet Est for EPS of $8.55 - marketscreener.com

04:09 AM

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions By Reuters - Investing.com

04:09 AM

04:08 AM

Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy - Investor's Business Daily

04:08 AM

04:05 AM

Gilead Raises 2026 Sales Forecast, Cuts Profit Outlook Due to Acquisitions - U.S. News Money

04:05 AM

04:04 AM

Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q1 Adjusted EPS $2.03 per Share - marketscreener.com

04:04 AM

04:03 AM

Earnings Flash (GILD) Gilead Sciences Posts Q1 Revenue $7B, vs. FactSet Est of $6.91B - marketscreener.com

04:03 AM

04:02 AM

Gilead Sees 2026 Loss on $11.5 Billion in Deal-Related Costs - Bloomberg.com

04:02 AM

04:01 AM

Gilead Sciences Announces First Quarter Financial Results - Yahoo Finance

04:01 AM

04:00 AM

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - GlobeNewswire Inc.

04:00 AM

03:31 AM

Gilead earnings up next: Can Yeztugo deliver after buyout blitz? By Investing.com - Investing.com Nigeria

03:31 AM

03:29 AM

Gilead earnings up next: Can Yeztugo deliver after buyout blitz? - Investing.com

03:29 AM

03:17 AM

Gilead Accuses Pharmacies Of Selling Counterfeit HIV Drugs - Law360

03:17 AM

01:10 AM

Gilead Sciences shares decline 1.36% ahead of first quarter earnings - Mint

01:10 AM

10:45 AM

Gilead guides for earnings loss after M&A mania, but bumps up sales expectations - FirstWord Pharma

10:45 AM

10:42 AM

Gilead wipes out most of Arcellx workforce - BioSpace

10:42 AM

10:08 AM

A Look At Gilead Sciences (GILD) Valuation After FDA Priority Review For New HIV Tablet - simplywall.st

10:08 AM

09:06 AM

WealthShield Partners LLC Takes $1.73 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat

09:06 AM

08:53 AM

Lilly, Gilead lead pharma’s M&A boom - Pharma Voice

08:53 AM

07:56 AM

Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead - Benzinga

07:56 AM

04:33 AM

Indivisible Partners Purchases New Stake in Gilead Sciences, Inc. $GILD - MarketBeat

04:33 AM

03:12 AM

Alecta Tjanstepension Omsesidigt Makes New $99.95 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat

03:12 AM

01:02 AM

California court weighs forcing Gilead to invest in safer HIV drugs - mezha.net

01:02 AM

May 06, 2026

7 months after last layoffs, Bay Area biotech giant does another round - SFGATE

May 06, 2026

California Justices Scrutinize Gilead Patients’ Liability Theory - Bloomberg Law News

May 06, 2026

Bay Area biotech takes another hit as Gilead announces major job cuts - SFGATE

May 06, 2026

California's highest court leans toward Gilead in considering drugmakers' 'duty to innovate' - Reuters

May 06, 2026

Airbnb, McKesson, Gilead and more set to report earnings Thursday By Investing.com - Investing.com Nigeria

May 06, 2026

Airbnb, McKesson, Gilead and more set to report earnings Thursday - Investing.com

May 06, 2026

Gilead Sciences Q1 2026 Earnings Preview: Steady growth ahead? (GILD:NASDAQ) - Seeking Alpha

May 06, 2026

Can We End the HIV Epidemic Once and for All? This Researcher Thinks So. - Men's Health

May 06, 2026

Madrigal MASH drug beats expectations; Gilead cuts jobs; investment firm debuts - Endpoints News

May 06, 2026